source
- Approaching First-Line Treatment in PD-L1 CPS <1 HER2-Positive GEAZanidatamab’s dual HER2 binding shows striking single-agent activity in gastric and biliary cancers, hinting at synergy beyond pertuzumab-trastuzumab blockade.onclive · 2mo ago↗ source
- Co-Occurring Mutations in NSCLC: Influence on Prognosis and Immunotherapy ResponseLearn how STK11 and MTAP loss reshape NSCLC prognosis, immunotherapy response, and open doors to dual-checkpoint and PRMT5 inhibitor trials.onclive · 2mo ago↗ source
- Evaluating Observational and Propensity Matched Studies in Metastatic Castration Sensitive Prostate Cancer (mCSPC)Experts weigh real‑world evidence for prostate cancer drug comparisons, explaining bias risks, data quality, and how it complements trials.